LeMaitre Vascular Inc. (NASDAQ:LMAT) picked up Angiotech Pharmaceuticals Inc.’s (NASDAQ:ANPI) Lifespan vascular graft business for $2.8 million and spiked a distribution deal Angiotech had with former Lifespan owner Edwards Lifesciences Corp. (NYSE:EW). Burlington, Massachusetts-based LeMaitre said it paid a multiple of 1.8 times the Lifespan revenues from the last 12 months for the vascular prosthesis, […]
The most promising application of Athersys Inc.'s (NASDAQ:ATHX) stem cell technology lies in treating stroke victims, according to a Morningstar Inc. analyst. "It's really market potential that leads us to believe that stroke is the most promising indication," said Lauren Migliore.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Athersys Inc. (NASDAQ: ATHX) has received the regulatory thumbs-up to begin a Phase 2 clinical trial of its MultiStem stem cell treatment for inflammatory bowel disease.
A group representing former shareholders of Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) subsidiary Quill Medical Inc. are suing both companies. QSR Holdings Inc. alleges that Angiotech concealed damaging information about the sales performance of a Quill product prior to Angiotech's acquisition of the company. It also alleges that Angiotech acted to deliberately reduce future milestone-related payments to QSR. Cleveland's Athersys is an Angiotech partner.
Athersys Inc. CEO Gil Van Bokkelen has been elected chairman of the The Alliance for Regenerative Medicine.
Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) deferred $9.7 million in interest payments on debt that were due Oct. 1, looking to "effectuate a transaction that would materially reduce the company's existing debt levels," the company said. Angiotech is working with Cleveland, Ohio-based Athersys to develop an adult stem cell therapy for heart attack patients.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Robert Edwards of Britain, an 85-year-old professor emeritus at the University of Cambridge who started working on in-vitro fertilization as early as the 1950s, won the 2010 Nobel Prize in medicine on Monday for developing the breakthrough that has helped millions of infertile couples worldwide have children, according to the Associated Press in the Washington Post.
Athersys Inc. reported more positive results from an ongoing Phase 1 clinical trial of its adult stem cell therapy for the treatment of heart-attack patients.
Athersys Inc.'s stem cell therapy has been granted orphan drug designation by the Food and Drug Administration for graft-versus-host disease.
Athersys Inc.'s (NASDAQ:ATHX) stem cell therapy showed positive results in an early preclinical investigation of its effects in treating traumatic brain injury.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
An FDA panel's decision to reject the obesity drug lorcaserin shouldn't affect Athersys Inc.'s (NASDAQ: ATHX) development of a similar drug, the Cleveland-based company's chief executive said.
RTI Biologics Inc. plans to develop and commercialize implants based on Athersys' Multipotent Adult Progenitor Cell (MAPC) technology.
As of Sept. 9, Michael Sheffery, a general partner with New York-based venture firm OrbiMed Advisors, no longer is a member of Athersys' board.
A judge's ruling that blocks federal funding for embryonic stem cell research triggered a tumble for shares of Cleveland biopharmaceutical company Athersys Inc. (NASDAQ: ATHX) -- even though its business involves only adult stem cells.
WBB Securities analyst Steve Brozak isn't sure whether people understand how much better the stem cell therapy of Cleveland, Ohio-based Athersys Inc. is for treating heart attacks than the standard-of-care treatment. Brozak raised his rating on Athersys stock to "strong buy" from "buy" in light of clinical evidence that could change the way heart attack patients are treated.